RT Journal Article
T1 Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers.
A1 López-García, M Ángeles
A1 Carretero-Barrio, Irene
A1 Pérez-Míes, Belén
A1 Chiva, Miguel
A1 Castilla, Carolina
A1 Vieites, Begoña
A1 Palacios, José
K1 HER2
K1 breast cancer
K1 estrogen receptor
K1 luminal
K1 progesterone receptor
K1 screening
K1 triple negative
AB Conflicting results have been reported regarding the prevalence of screen-detected human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas and non-screen detected HER2-positive breast carcinomas. To address this issue, we evaluated the prevalence of HER2-positive breast carcinomas in two independent regional screening programs in Spain. The clinicopathologic and immunohistochemical characteristics of 479 (306 and 173) screen-detected breast carcinomas and 819 (479 and 340) non-screen-detected breast carcinomas diagnosed in women between 50 and 69-year-olds were compared. The prevalence of HER2-positive breast carcinomas was 8.8% and 6.4% in the two series of screen-detected tumors, compared with 16.4% and 13% in non-screen-detected carcinomas. These differences were statistically significant. This lower prevalence of HER2-positive in-screen-detected breast carcinomas was observed in both hormone receptor positive (luminal HER2) and hormone-receptor-negative (HER2 enriched) tumors. In addition, a lower prevalence of triple-negative and a higher prevalence of luminal-A breast carcinomas was observed in screen-detected tumors. Moreover, a literature review pointed out important differences in subrogate molecular types in screen-detected breast carcinomas among reported series, mainly due to study design, technical issues and racial differences.
SN 2072-6694
YR 2020
FD 2020-06-15
LK https://hdl.handle.net/10668/27491
UL https://hdl.handle.net/10668/27491
LA en
DS RISalud
RD Apr 14, 2025